Molecular Partners AGNASDAQ:MOLN
- LAST PRICE3.9400
- TODAY'S CHANGE (%)-0.0100 (-0.2532%)
- Bid / Lots3.7600/ 1
- Ask / Lots4.3400/ 6
- Open / Previous Close3.9300 / 3.9500
- Day Range
- 52 Week Range
- Volume2,490
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MOLN |
|---|---|---|
| 11:13 ET | 140 | 3.93 |
| 12:34 ET | 124 | 3.78 |
| 12:50 ET | 145 | 3.85 |
| 01:03 ET | 100 | 3.94 |
Mar 26, 2024
Press Release: Molecular Partners Publishes Invitation to Annual General Meeting 2024, from 9:26AM ET on Tuesday Mar 26, 2024 by Dow Jones
9:26AM ET on Tuesday Mar 26, 2024 by Dow JonesMolecular Partners Publishes Invitation to Annual General Meeting 2024, from 9:26AM ET on Tuesday Mar 26, 2024 by Dow Jones
9:26AM ET on Tuesday Mar 26, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Molecular Partners AG | 142.3M | -1.9x | --- |
Vaxart Inc | 158.1M | -1.5x | --- |
Syros Pharmaceuticals Inc | 141.5M | -1.0x | --- |
ProQR Therapeutics NV | 166.4M | -5.6x | --- |
Sagimet Biosciences Inc | 145.5M | -3.2x | --- |
Coya Therapeutics Inc | 122.2M | -9.7x | --- |
Company Information
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
Contact Information
- Headquarters
- Wagistrasse 14SCHLIEREN, Switzerland 8952
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- William Burns
- Chief Executive Officer, Executive Director, Member of the Management Board
- Patrick Amstutz
- Chief Operating Officer, Member of the Management Board
- Alexander Zurcher
- Executive Vice President - People and Community, Member of the Management Board
- Renate Gloggner
- Executive Vice President - Projects, Member of the Management Board
- Michael Stumpp
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $142.3M |
|---|---|
Revenue (TTM) | $7.7M |
Shares Outstanding | 36.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.08 |
Book Value | $5.89 |
P/E Ratio | -1.9x |
Price/Sales (TTM) | 18.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -868.26% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
